论文部分内容阅读
以B72.3单抗的对应肿瘤相关糖蛋白抗原72(TAG-72)为免疫源,采用细胞融合技术制备出了B72.3第二代单克隆抗体72-45和72-142。上述单抗的免疫组化分析结果表明,除同胎儿和成人皮脂腺、汗腺和小肠上皮细胞呈一定程度的反应外,同其它正常组织器官均呈阴性反应。相反,单抗72-45在大肠癌的阳性率为100%,肺腺癌为80%。单抗72-142在大肠癌阳性率为40.5%,肺腺癌为79.5%。结果提示上述单抗对恶性肿瘤的诊断和治疗具有一定的潜在应用价值。
B72.3 monoclonal antibodies 72-45 and 72-142 of the second generation were prepared by the cell fusion technique using the corresponding tumor-associated glycoprotein antigen 72 (TAG-72) of B72.3 monoclonal antibody as an immunogenic source. Immunohistochemical analysis of the above monoclonal antibodies showed that, in addition to the fetus and adult sebaceous glands, sweat glands and small intestine epithelial cells showed a certain degree of response, with other normal tissues and organs showed a negative reaction. In contrast, mAbs 72-45 showed a positive rate of 100% for colorectal cancer and 80% for lung adenocarcinoma. The positive rate of monoclonal antibody 72-142 in colorectal cancer was 40.5% and lung adenocarcinoma was 79.5%. The results suggest that the above monoclonal antibody has certain potential value in the diagnosis and treatment of malignant tumors.